FDA Outlines Genome Editing Safety Guidance for Therapies

The U.S. Food and Drug Administration has released a draft guidance outlining safety assessment standards for human gene therapy products that incorporate genome editing technologies, marking a step toward streamlining development pathways for advanced therapies. Announced on April 14, 2026, the document is designed to support sponsors in evaluating risks associated with genome editing while […] The post FDA Outlines Genome Editing Safety Guidance for Therapies first appeared on World Pharma Today .